| abstract |
According to the method, treatment induced for a short period of time with the LH-RH antagonist is carried out, from 4 to 12 weeks. In a post-treatment embodiment, one or more active agents selected from the group consisting of contraceptive, preferably oral, non-steroidal anti-rheumatic agent, analgesic, androgen other than 17-alpha-alkyl substituted testosterone, or a combination of them. The invention also relates to a pharmaceutical composition comprising an LH-RH antagonist and one or more active agents selected from the group consisting of a contraceptive, preferably an oral, non-steroidal anti-rheumatic agent, analgesic, androgen other than 17-alpha-alkyl substituted testosterone. or a combination of them. |